PDCD1 and neoplasm: Systemic treatment with antibodies can trigger effects on tumor cells (over-) expressing designated surface antigens, like the epidermal growth factor receptor (EGFR), programmed cell death protein 1 (PD-1), its ligand (PD-L1), as well as the cytotoxic T lymphocyte-associated protein 4 (CTLA-4).